Travere Therapeutics Inc (NAS:TVTX)
$ 6.44 -0.12 (-1.83%) Market Cap: 490.27 Mil Enterprise Value: 462.38 Mil PE Ratio: 0 PB Ratio: 6.64 GF Score: 58/100

Travere Therapeutics Inc to Discuss the Regulatory Update Call Transcript

Oct 13, 2022 / 08:30PM GMT
Release Date Price: $23.19 (+3.99%)
Operator

Good day, and welcome to the Travere Therapeutics Corporate Update Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Chief Financial Officer, Chris Cline. Please go ahead, sir. Thank you.

Christopher Cline
Travere Therapeutics, Inc. - CFO & Senior VP of IR and Corporate Communications

Great. Thank you, Cynthia. Good afternoon, and thank you all for joining us on short notice today. We'll be covering a regulatory update for sparsentan in IgA nephropathy. A copy of the press release announcing the update is available on our website.

Today's call will be led by our Chief Executive Officer, Dr. Eric Dube; and our Chief Medical Officer, Dr. Jula Inrig; our Senior Vice President of Research and Development, Dr. Bill Rote, will also join us for the Q&A session.

Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot